ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACXP vs ABBV // GROSS PROFIT MARGIN

Acurx Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ACXP 0 — ABBV 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACXP VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACXP ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 70.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 29.00% -64.00 ABBV /roic <GO>
EV/EBITDA & P/E Valuation — 33.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.47% — TIE /fcf-yield <GO>
Operating Margin — 24.60% — TIE /operating-margins <GO>
Net Profit Margin — 6.90% — TIE /net-margins <GO>
Revenue Growth (YoY) — 8.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 ABBV /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.6 65.1 -38.49 ABBV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 113.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.9M $513.86B -$513.85B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACXP REV ABBV REV ACXP GROSS % ABBV GROSS % ACXP FCF ABBV FCF
FY 2025 $0 $61.16B — 70.2% -$6.8M $17.82B
FY 2024 $0 $56.33B — 70.0% -$10.4M $17.83B
FY 2023 $0 $54.32B — — -$9.8M $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACXP // BETA —
ABBV // BETA 1.15